oldberkeley---Amarin's VASCEPA (icosapent ethyl) capsules are the first FDA approved EPA*-only Omega-3 fatty acid. It is a synthetic derivative of EPA.
CaPre® is a highly purified omega-3 phospholipid concentrate derived from krill oil. The active ingredient of CaPre® is a mixture of concentrated omega-3 fatty acids purified from krill oil and developed as an oral formulation. CaPre® contains EPA and DHA bound to phospholipids as well as free EPA and DHA for a total concentration of approximately two-thirds phospholipids and approximately 30% EPA and DHA.
. In addition to targeting the reduction of high to very high triglycerides, Acasti’s longer-term objective is to demonstrate that CaPre® can also reduce LDL (bad cholesterol) and raise HDL (good cholesterol). Vascepa targets very high trigs.
However, to Acasti's knowledge, CaPre® is the only omega-3 phospholipid product being developed with a potential to demonstrate a clear clinical superiority in treating triglycerides, LDL and HDL. To date, no competing product currently on the market has demonstrated efficacy in treating all three indications.
Krill oil not only provides an excellent source of omega essential fatty acids, but it also contains phospholipids, flavonoids, choline and an incredible antioxidant called astaxanthin. In typical fish oils, the omega-3,6,9 fatty acids are found in the triglyceride form whereas in krill oil they are hooked up in a double chain phospholipid structure. These double chain structures closely resembling that of brain phospholipids and cell membranes making it highly absorbable and bioavailable to the body and far more superior than fish oil. Choline, an essential nutrient found in krill oil, is used in the structure of cell membranes, protects the liver from accumulating fats, and is important to the transmission of nerve impulses. Not only is the absorption of krill oil higher than fish oil but the antioxidant potential is 48 times higher as well. Vitamin A, D and E are critical components of krill oil along with the most potent antioxidant, astaxanthin.
Over 230 patients completed the study, exceeding the targeted number of evaluable patients. From this patient population, 88% had high baseline triglycerides of 200 to < 500 mg/dL, which is considered a harder-to-treat group.
Many health organizations, such as American Heart Association (AHA), American College of Cardiology, US National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III), and the European Society of Cardiology have issued ecommendations to increase the intake of omega-3 fatty acids above the typical level of consumption in the diets of most developed countries [Harris 2008]. For secondary prevention in patients with established CHD, the AHA recommends increasing intake of EPA + DHA to 1 g/day in the form of oily fish or fish oil
capsules; and for individuals with hypertriglyceridemia, the recommendation is 2–4 g/day under the supervision of a physician. There are currently at least four prescription-grade omega-3 products available or in development, Lovaza® (capsules contain DHA, EPA, and other fish oils in the form of the ethyl ester), Vascepa® (contains only synthetic derivative of EPA), Epanova® (capsules contain EPA and DHA in their free fatty acid form) and CaPre®, which is the prescription drug candidate of Acasti Pharma composed of a highly purified EPA- and DHA-phospholipid concentrate derived from krill oil.
News 
Market Data 
Discover 
